Imipenem: Broad-Spectrum Semisynthetic Thienamycin Antibiotic for Antibacterial Research

Executive Summary: Imipenem, a semisynthetic thienamycin antibiotic, exhibits potent broad-spectrum antibacterial activity against both gram-negative and gram-positive bacteria, including multidrug-resistant strains (APExBIO product page). It is stable against many beta-lactamases, enabling its use in resistance studies (Chen et al. 2025). Imipenem acts by binding specifically to PBPs—especially PBP-2, PBP-1a, and PBP-1b—interfering with peptidoglycan polymerization and leading to cell death. In vitro, concentrations of 30–60 mg/L enhance phagocytosis without altering superoxide production, and in vivo, intraperitoneal administration in sepsis models improves survival outcomes. These properties make Imipenem a reference molecule in both antibacterial mechanism and immune modulation research.

Biological Rationale

Imipenem is a member of the carbapenem class, derived from thienamycin, and is chemically described as (5R,6S)-3-[2-(aminomethylideneamino)ethylsulfanyl]-6-[(1R)-1-hydroxyethyl]-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid (molecular weight: 299.35). Its unique beta-lactam structure confers resistance to most beta-lactamases produced by bacteria, a major cause of multidrug resistance (Chen et al. 2025). Imipenem's broad-spectrum profile makes it valuable in research targeting both gram-negative and gram-positive pathogens, including aerobic and anaerobic species. Its clinical and preclinical relevance is amplified by the global rise of carbapenem-resistant Enterobacteriaceae (CRE), where the study of imipenem resistance mechanisms is critical (Imipenem in Translational Antibacterial Research contrasts by offering strategic recommendations for resistance mitigation, which this article updates with recent molecular epidemiology findings).

Mechanism of Action of Imipenem

Imipenem exerts its bactericidal effect by binding to penicillin-binding proteins (PBPs), specifically PBP-2, PBP-1a, and PBP-1b in Escherichia coli and Pseudomonas aeruginosa. This binding inhibits the transpeptidation and carboxypeptidation steps in peptidoglycan synthesis, disrupting the bacterial cell wall and causing osmotic lysis (APExBIO). By being stable against hydrolysis by most beta-lactamases, imipenem remains active where many other beta-lactam antibiotics fail. The high affinity for PBPs and resistance to enzymatic degradation underpins its role in studies of bacterial cell wall synthesis inhibition and antibiotic resistance mechanisms. In vitro, imipenem enhances phagocytosis in human polymorphonuclear leukocytes at concentrations of 30 and 60 mg/L, without affecting reactive oxygen species production or lymphocyte proliferation.

Evidence & Benchmarks

• Imipenem demonstrates activity against both gram-negative and gram-positive aerobic and anaerobic bacteria at clinically relevant concentrations (APExBIO).
• The positive rate of carbapenemase-encoding genes (CEGs) in carbapenem-resistant Enterobacter cloacae isolates was 85.19% (46/54) in hospitals studied in Guangdong, China (Chen et al. 2025).
• Resistance rates to imipenem were significantly higher in CEG-positive vs. CEG-negative groups (P<0.05; broth microdilution) (Chen et al. 2025).
• In vitro, imipenem at 30–60 mg/L enhances neutrophil phagocytosis without increasing superoxide anion production (APExBIO).
• In vivo, 120 mg/kg intraperitoneal imipenem improves survival in septic rat models, especially when combined with low-dose cyclophosphamide, but may decrease IL-10 expression and impair gut barrier function (APExBIO).
• Imipenem’s stability in water (≥29.9 mg/mL with gentle warming) and insolubility in ethanol and DMSO facilitates its use in diverse experimental protocols (APExBIO).
• Plasmid conjugation experiments showed a 95.65% success rate for transfer of CEGs among Enterobacter cloacae strains, highlighting the rapid dissemination challenge for carbapenem resistance (Chen et al. 2025).

Applications, Limits & Misconceptions

Imipenem is a critical tool in antibacterial research, including studies of resistance, immune modulation, and translational animal models. It is commonly used to benchmark the efficacy of new beta-lactamase inhibitors and to dissect mechanisms of gram-negative and gram-positive pathogen clearance.

For a more detailed discussion of Imipenem’s role as a broad-spectrum antibacterial agent and immune modulator, see Imipenem: A Broad-Spectrum Antibiotic for Antibacterial Research, which this article updates by integrating newly published epidemiological data and recent in vivo findings on immune function.

Common Pitfalls or Misconceptions

• Not effective against all beta-lactamase types: Imipenem is stable against most, but not all, beta-lactamases—especially metallo-beta-lactamases such as NDM-1, which confer resistance (Chen et al. 2025).
• Not for clinical or diagnostic use: APExBIO's Imipenem (P10075) is for scientific research only and is not intended for medical or diagnostic applications (APExBIO).
• Limited effect in presence of high-level carbapenemase producers: Strains with high plasmid-borne CEG expression may show resistance even at high imipenem concentrations (Chen et al. 2025).
• Pharmacokinetic limitations: Imipenem has a relatively short in vivo half-life unless combined with DHP-I inhibitors (not included in the research-grade product) (APExBIO).

Workflow Integration & Parameters

Imipenem is provided as a solid, shipped with blue ice, and should be stored at -20°C. It is water soluble (≥29.9 mg/mL with gentle warming), but insoluble in ethanol and DMSO. Typical in vitro working concentrations range from 30 to 60 mg/L, supporting studies of phagocytosis and cell wall inhibition. For in vivo rodent models, intraperitoneal doses of 120 mg/kg are reported in sepsis protocols. Researchers should titrate concentrations based on target organism and experimental design. The product is intended exclusively for research use and should not be used for human or veterinary purposes. For protocol guidance and product specifications, refer to the Imipenem (P10075) kit page from APExBIO.

Conclusion & Outlook

Imipenem remains a gold-standard reference for studying mechanisms of bacterial cell wall synthesis inhibition, beta-lactamase-mediated resistance, and immune response modulation in both gram-negative and gram-positive bacteria. The continued emergence of carbapenemase-encoding genes, especially those conferring resistance to imipenem, highlights the need for ongoing molecular surveillance and innovative therapeutic strategies. APExBIO’s research-grade Imipenem provides a robust platform for antibacterial and immunological investigations, enabling researchers to address urgent questions in antibiotic resistance and sepsis modeling.